Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.

Journal of cancer research and clinical oncology - 1 Jul 2023

Kanduła Zuzanna, Janowski Michał, Więckowska Barbara, Paczkowska Edyta, Lewandowski Krzysztof

Abstract excerpt

INTRODUCTION: Despite comparatively favourable prognosis in polycythemia vera (PV) patients (pts), the overall survival is shorter compared to the age-matched general population. The aim of the study was to evaluate the impact of chosen laboratory and genetic factors on the individual disease outcome, i.e. risk of thrombosis, myelofibrosis/blastic transformation and death. MATERIALS AND METHODS: The study group...

Topics

Join the communities discussing this publication.

Gene Frequency
Janus Kinase 2
Mutation
Nucleotides
Polycythemia Vera

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 36242602
DOI: 10.1007/s00432-022-04327-0
PMCID: PMC10349754

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.PMID 36242602Read ↗

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

Features and Allele Frequency of JAK2 Exon 12-Mutated Polycythemia Vera in Comparison with JAK2V617F-Mutated Disease.Semantic proximity Read ↗

Molecular Characterization of Polycythemia VeraSemantic proximity Read ↗

Genetic Background of Polycythemia Vera.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

JAK2 V617F allele burden in polycythemia vera: burden of proof.Semantic proximity Read ↗

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Semantic proximity Read ↗

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burdenSemantic proximity Read ↗

ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients.Semantic proximity Read ↗

The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates.Semantic proximity Read ↗

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.